PharmGKB summary: Cery important pharmacogene information for UGT1A1

Pharmacogenetics and Genomics

Volumn 24, Issue 3, 2014, Pages 177-183

  Barbarino, Julia M ^a   Haidar, Cyrine E ^b   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Atazanavir; Crigler Najjar syndrome; Gilbert's syndrome; Indinavir; Irinotecan; Pharmacogenetics; UGT1A1

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; METABOLISM; PHARMACOGENETICS; REVIEW;

ANTINEOPLASTIC AGENTS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84894201503     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000024     Document Type: Article

References (90)

1. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008; 9:703-715
2. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: Implications for cancer risk and cancer therapeutics. Pharmacogenetics 2003; 13:517-523
3. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15:677-685
4. Bushey RT, Dluzen DF, Lazarus P. Importance of UDPglucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism. Drug Metab Dispos 2013; 41:170-179
5. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142:778-787
6. Van Es HH, Bout A, Liu J, Anderson L, Duncan AM, Bosma P, et al. Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37. Cytogenet Cell Genet 1993; 63:114-116
7. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11:357-368
8. Strassburg CP, Lankisch TO, Manns MP, Ehmer U. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): From Gilbert's syndrome to genetic organization and variability. Arch Toxicol 2008; 82:415-433
9. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010; 87:65-73
10. Girard H, Levesque E, Bellemare J, Journault K, Caillier B, Guillemette C. Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics 2007; 17:1077-1089
11. Bellemare J, Rouleau M, Harvey M, Tetu B, Guillemette C. Alternativesplicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. Pharmacogenomics J 2010; 10:431-441
12. Innocenti F, Ratain MJ. ''Irinogenetics'' and UGT1A: From genotypes to haplotypes. Clin Pharmacol Ther 2004; 75:495-500
13. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, et al. Polymorphic gene regulation and interindividual variation of UDPglucuronosyltransferase activity in human small intestine. J Biol Chem 2000; 275:36164-36171
14. Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 1998; 54:647-654
15. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269:17960-17964
16. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616
17. Schauer R, Stangl M, Lang T, Zimmermann A, Chouker A, Gerbes AL, et al. Treatment of Crigler-Najjar type 1 disease: Relevance of early liver transplantation. J Pediatr Surg 2003; 38:1227-1231
18. Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: Identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005; 25:325
19. Sneitz N, Bakker CT, de Knegt RJ, Halley DJ, Finel M, Bosma PJ. Crigler-Najjar syndrome in The Netherlands: Identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat 2010; 31:52-59
20. Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 1969; 47:395-409
21. Pett S, Mowat AP. Crigler-Najjar syndrome types I and II. Clinical experience-King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation. Mol Aspects Med 1987; 9:473-482
22. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94:2385-2391
23. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype. Hum Mutat 2000; 16:297-306
24. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175
25. Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr 2012; 171:11-15
26. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95:8170-8174
27. Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, et al. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1 28 polymorphism. Drug Metab Dispos 2007; 35:2270-2280
28. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 2002; 62:446-450
29. Monaghan G, McLellan A, McGeehan A, Li Volti S, Mollica F, Salemi I, et al. Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 1999; 134:441-446
30. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46:21-26
31. Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, et al. Relationship between hyperbilirubinaemia and UDPglucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics 2006; 16:321-329
32. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1998; 1406:267-273
33. Maruo Y, Nishizawa K, Sato H, Doida Y, Shimada M. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999; 103:1224-1227
34. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, et al. Characterization of benzo(a)pyrene-Trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDPglucuronosyltransferase enzymes. Cancer Res 2002; 62:1978-1986
35. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002; 30:1266-1273
36. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, et al. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 2005; 42:448-457
37. Adegoke OJ, Shu XO, Gao YT, Cai Q, Breyer J, Smith J, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 2004; 85:239-245
38. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60:950-956
39. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet 2012; 205:163-167
40. Tang KS, Chiu HF, Chen HH, Eng HL, Tsai CJ, Teng HC, et al. Link between colorectal cancer and polymorphisms in the uridinediphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol 2005; 11:3250-3254
41. James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and-negative breast cancer: A nested case-control study. Cancer Prev Res (Phila) 2011; 4:1626-1635
42. Tsezou A, Tzetis M, Giannatou E, Gennatas C, Pampanos A, Kanavakis E, et al. Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women. Genet Test 2007; 11:303-306
43. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001; 10:711-714
44. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, et al. UDPglucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 2004; 6:R488-R498
45. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56:1535-1543
46. Ekblom K, Marklund SL, Jansson JH, Osterman P, Hallmans G, Weinehall L, et al. Plasma bilirubin and UGT1A1 28 are not protective factors against first-Time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet 2010; 3:340-347
47. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: Using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012; 12:16
48. Chen YH, Hung SC, Tarng DC. Serum bilirubin links UGT1A1 28 polymorphism and predicts long-Term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011; 6:567-574
49. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: Three Mendelian randomization studies and a meta-Analysis. J Intern Med 2013; 273:59-68
50. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1 28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006; 114:1476-1481
51. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1 28 allele and coronary heart disease: The Rotterdam Study. Clin Chem 2003; 49:1180-1181
52. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9:591-599
53. Haverfield EV, McKenzie CA, Forrester T, Bouzekri N, Harding R, Serjeant G, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005; 105:968-972
54. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1 28 genotype and irinotecan-induced neutropenia: Low doses also increase risk. Clin Cancer Res 2010; 16:3832-3842
55. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1 28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 2007; 99:1290-1295
56. Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, et al. UGT1A1 6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009; 14:136-142
57. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr 2010; 24:104-123
58. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191
59. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617
60. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, et al. Gilbert's Syndrome and irinotecan toxicity: Combination with UDPglucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008; 17:695-701
61. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9:539-549
62. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115:3858-3867
63. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002; 30:694-700
64. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004; 103:67-72
65. Trontelj J, Marc J, Zavratnik A, Bogataj M, Mrhar A. Effects of UGT1A1 28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 2009; 67:437-444
66. Danoff TM, Campbell DA, McCarthy LC, Lewis KF, Repasch MH, Saunders AM, et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4:49-53
67. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, et al. Gilbert's disease and atazanavir: From phenotype to UDPglucuronosyltransferase haplotype. Hepatology 2006; 44:1324-1332
68. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260:199-202
69. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27:2457-2465
70. Lévesque E, Belanger AS, Harvey M, Couture F, Jonker D, Innocenti F, et al. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther 2013; 345:95-101
71. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: Functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10:629-644
72. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226-1236
73. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388
74. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:678-682
75. Camptosar [package insert]. New York, NY: Pfizer Inc.; 2012
76. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: From bench to byte-An update of guidelines. Clin Pharmacol Ther 2011; 89:662-673
77. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061-3068
78. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10:5151-5159
79. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecanbased chemotherapy. Cancer 2006; 106:1007-1016
80. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25:2594-2600
81. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729-1739
82. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, et al. Gilbert syndrome and the development of antiretroviral therapy-Associated hyperbilirubinemia. J Infect Dis 2005; 192:1381-1386
83. Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB, et al. Genetic factors influencing severe atazanavir-Associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1 28 allele frequency. Clin Infect Dis 2010; 51:101-106
84. Turatti L, Sprinz E, Lazzaretti RK, Kuhmmer R, Agnes G, Silveira JM, et al. Short communication: UGT1A1 28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. AIDS Res Hum Retroviruses 2012; 28:1015-1018
85. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12:725-733
86. Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M, et al. Linkage disequilibrium of UGT1A1 6 and UGT1A1 28 in relation to UGT1A6 and UGT1A7 polymorphisms. Oncol Rep 2006; 16:801-806
87. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926
88. O'Reilly S, Rowinsky EK. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol 1996; 24:47-70
89. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, et al. Clinical significance of UDP-glucuronosyltransferase 1A1 6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: A prospective multi-institutional study. Oncology 2009; 76: 315-321
90. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, et al. Role of UGT1A1 6, UGT1A1 28 and ABCG2 c.421C > A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98:1461-1467